PPT-Imatinib

Resistance Geoffrey L Uy MD Associate Professor of Medicine Division of Oncology Natural History of CML Chronic Phase Accelerated Phase Blast Phase Duration 35 yrs untreated Varies. M. yeloid Leukemia. Amer Rassam, M.D.. Learning Objectives. Myeloproliferative. disorders (MPDs). Molecular . genetics of chronic myeloid . leukemia. Clinical manifestations and diagnosis of chronic myeloid leukemia. and. Breast Cancer Conference. CML . ASH Update. Michael J. Mauro, MD. CML Abstracts. Novel Agents. Abstract # 109. : . A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib or with the T315I Mutation. Evidence-based Management . of GIST. Program Goals. GIST. Current Treatment Paradigm. What is GIST?. What Causes GIST?. GIST: Treatment. Polling Question #1. Imatinib: Clinical Trial Results. Imatinib: Early Stage GIST. Definition of Gastrointestinal Stromal Tumor . the most common mesenchymal malignancy of (GI) tract. the diagnostic criteria for GIST remained controversial and somewhat confusing. Pathology Terms that Encompass the Spectrum of Gastrointestinal Stromal Tumors. chromosomal positive acute lymphoblastic leukemia. Jiong. HU. Blood & Marrow Transplantation Center, . Rui. Jin Hospital, Shanghai Jiao Tong University School of Medicine. 1. Role of TKI: overview. . University. of Bologna . Advances. in . cancer. target . pathways. . Roma 8 aprile 2016. Targeting. . molecular. . pathways. . in GIST . La . risposta. ad . imatinib. . dipende. Sarcoma . Medical Oncology. The University of . Miami, Sylvester Cancer Center. Gastrointestinal Stromal . Tumor. Advanced Disease. jtrent@med.miami.edu. Background and Introduction. 4000 to 6000 new GIST are diagnosed in the United States each yr. Associate Professor . of Medicine. Division of Oncology. Natural History of CML. Chronic Phase. Accelerated Phase. Blast Phase. Duration. 3-5 . yrs. , untreated. Varies. Median. of months. Prognosis. Angela . Cioffi. , MD. Sarcoma Research Program coordinator. Mount Sinai Hospital, NY, USA. Istituto. . Europeo. . di. . Oncologia. , IRCSS, Milan, Italy. Today. ’. s job. Review some of the key studies sarcoma that dictate present management. BONJOUR. Tolerance of . Imatinib. . Dasatinib. . and . Nilotinib. . in the . treatment. . of . C. hronic . Myeloid Leukemia.. International Conférence on . Toxicogenomics. and Drug Monitoring and . Amer Rassam, M.D.. Learning Objectives. Myeloproliferative. disorders (MPDs). Molecular . genetics of chronic myeloid . leukemia. Clinical manifestations and diagnosis of chronic myeloid leukemia. Overview of the treatment of chronic myeloid leukemia. A FIP risk criteria 3 ears of imatinib (n= 31) 5 Y ears of imatinib (n= 20) p - value 2 0 1 (5.0 ) 0. 7 3a ) 3 (15 ) 3b 9 (29 ) ) 5 0 1 (5.0 ) 6a 11 (35 ) 6 (30 ) 6b 6 (19 ) 5 (25 ) Vpresented as nu Dermatofibrosarcoma protuberans Fukai Leo Chuang, MD, and Juan M. Alcantar, MD �� &#x/MCI; 0 ;&#x/MCI; 0 ;Case Reportyearoldpreviously healthyAsianmale presented with right lower Metastasis of DFSP is rare, occurring in approximately 1% to 4% of cases, but is a definite risk and it can contribute to mortality associated with uncontrolled disease. Clinical aspects Imatinib inh